Sunvozertinib and Nafcillin Injection: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Nafcillin Injection
Sunvozertinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced sunvozertinib exposure and reduced efficacy of sunvozertinib
Interaction Deep Dive
Avoid coadministration of sunvozertinib with a strong or moderate CYP3A inducer as it may reduce sunvozertinib exposure, which may reduce the efficacy of sunvozertinib. In drug interaction studies, sunvozertinib AUC decreased by 48% and Cmax by 38% following concomitant administration of carBAMazepine (strong CYP3A inducer) 300 mg twice daily. Sunvozertinib AUC is predicted to decrease by 44% following concomitant administration of efavirenz (moderate CYP3A inducer) 600 mg once daily. If concomitant use cannot be avoided, increase the sunvozertinib dose from 200 mg to 400 mg. After discontinuing a strong or moderate CYP3A inducer, resume the sunvozertinib dose (7 to 14 days after discontinuing the strong or moderate CYP3A inducer) that was taken prior to initiating the strong or moderate CYP3A inducer1.
Why it happens (mechanism)
Induction of CYP3A-mediated metabolism of sunvozertinib
Literature reports
1 report — tap to read
a) In drug interaction studies, sunvozertinib AUC decreased by 48% and Cmax by 38% following concomitant administration of carBAMazepine (strong CYP3A inducer) 300 mg twice daily. Sunvozertinib AUC is predicted to decrease by 44% following concomitant administration of efavirenz (moderate CYP3A inducer) 600 mg once daily 1.
Common questions
Can I take Sunvozertinib and Nafcillin Injection together?
Reduced sunvozertinib exposure and reduced efficacy of sunvozertinib Always confirm with your pharmacist or prescriber before making any change.
How serious is the Sunvozertinib and Nafcillin Injection interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Sunvozertinib or Nafcillin Injection need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ZEGFROVY(TM) oral tablets, sunvozertinib oral tablets. Dizal (Jiangsu) Pharmaceutical Co. Ltd (per FDA), Shanghai, China, 2025.
Keep reading about Nafcillin Injection
Keep reading about Sunvozertinib
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist